title: [FGF/FGFR signalling: Implication in oncogenesis and perspectives].
abstract: Deregulation of FGF (fibroblast growth factor)/FGFR (fibroblast growth factor receptor) signalling leads to the promotion of several oncogenic mechanisms: proliferation, epithelial-mesenchymal transition, cytoskeleton modifications, migration and angiogenesis. Deregulation of this pathway is reported in various cancers at early stages, and can therefore be responsible for the emergence of the hallmarks of cancer. It is necessary to precise downstream pathways of FGFR signalling to understand its oncogenic potential. We will then describe its implications in different cancer types. Oncogenic mechanisms will be studied through the example of melanoma, in which deregulation of FGF/FGFR pathway is considered as a driver event and occurs in nearly 90% of cases. The FGF/FGFR signalling pathway is a putative therapeutic target. Numerous agents are in active development, operating through a selective or multi-targeted approach. Recent studies have shown rather disappointing results in non-selected patients, but promising results in patients with FGF/FGFR pathway alterations. A careful screening of patients is the key to a valuable evaluation of these new targeted molecular therapies.
authors.affiliation: Gustave-Roussy, département d'innovations thérapeutiques essais précoces, 94800 Villejuif-Grand Paris, France.
authors.forename: Ronan
authors.initials: R
authors.lastname: Flippot
authors.affiliation: Hôpital Louis-Pasteur, service d'oncologie-hématologie, 28630 Chartres-Le-Coudray, France.
authors.forename: Moumini
authors.initials: M
authors.lastname: Kone
authors.affiliation: Institut de cancérologie Lucien-Neuwirth, département de radiothérapie, 42270 Saint-Priest-en-Jarez, France.
authors.forename: Nicolas
authors.initials: N
authors.lastname: Magné
authors.affiliation: Hôpital Louis-Pasteur, service d'oncologie-hématologie, 28630 Chartres-Le-Coudray, France. Electronic address: svignot@ch-chartres.fr.
authors.forename: Stéphane
authors.initials: S
authors.lastname: Vignot
mesh_terms: D063646:Carcinogenesis / Q000235:genetics / Q000378:metabolism*; D002450:Cell Communication / Q000502:physiology; D002465:Cell Movement; D049109:Cell Proliferation; D003599:Cytoskeleton / Q000378:metabolism; D058750:Epithelial-Mesenchymal Transition; D005346:Fibroblast Growth Factors / Q000378:metabolism*; D006801:Humans; D008545:Melanoma / Q000209:etiology / Q000378:metabolism; D009389:Neovascularization, Pathologic / Q000209:etiology; D017468:Receptors, Fibroblast Growth Factor / Q000378:metabolism*; D015398:Signal Transduction
chemical_list: D017468:Receptors, Fibroblast Growth Factor; D005346:Fibroblast Growth Factors
keywords: Amplification; FGF receptor; Melanoma; Molecular targeted therapy; Mutation; Mélanome; Thérapie moléculaire ciblée